GNPX Stock — Genprex Inc.: Cash, EV, Pipeline

Share price

$3.45

Market cap

$2.8M

Cash

$15.2M

Enterprise value

-$12.4M

Balance sheet

Cash	$15.2M
Debt	$0.0M
Net cash	$15.2M
Enterprise value	-$12.4M
Basic shares	0.5M shares
Fully diluted shares	0.9M shares
Fully diluted market cap	$3.0M
Cash per share	$30.30

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading GNPX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	quaratusugene ozeplasmid	Phase 2	Small Cell Lung Cancer Extensive Stage	—
Apr 12 - May 24	quaratusugene ozeplasmid	Phase 2	Carcinoma, Non-Small Cell Lung	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

REQORSA

Phase 1/2 · Active Modality: Gene therapy (TUSC2 plasmid via ONCOPREX Delivery System)

Aliases quaratusugene ozeplasmid, GPX-001

Target TUSC2 (tumor suppressor candidate 2)

Partnerships MD Anderson: sponsored research agreement (Apr 2026) on REQORSA response biomarkers. Roche Diagnostics: collaboration (announced Aug 2026) to validate TROP2 biomarkers for patient selection in NSCLC clinical trials.

Indications

Late-stage EGFR-mutated NSCLC progressed on Tagrisso (+ osimertinib), Acclaim-1 (Phase 1/2)
Extensive-stage SCLC maintenance (+ atezolizumab), Acclaim-3 (Phase 1/2)

Catalysts

— 2026 (year-end)
— H1 2027

Status note Lead oncology candidate. Acclaim-1 (NSCLC) in Phase 2a expansion (FDA Fast Track); Acclaim-3 (ES-SCLC, with Tecentriq as maintenance therapy) in Phase 2 expansion (FDA Fast Track + Orphan Drug).

GPX-002

Preclinical · Active Modality: Gene therapy (AAV)

Target Pdx1 / MafA

Partnerships University of Pittsburgh: exclusive worldwide license (New UP License Agreement, Feb 2025; Pdx1/MafA under insulin, glucagon, MafB promoters) + sponsored research in animal models; subsidiary Convergen Biotech formed (Feb 2025) for potential separation of the diabetes program

Indications

Type 1 diabetes (Preclinical)
Type 2 diabetes (Preclinical)

Status note Preclinical. FDA pre-IND meeting for type 1 diabetes held Feb 19, 2026; toxicology studies underway to enable IND filing. Company also evaluating a non-viral LNP second-generation delivery approach.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	quaratusugene ozeplasmid
Lead indication	Small Cell Lung Cancer Extensive Stage
Lead phase	Phase 2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05703971	Phase 2	Recruiting	Sponsor	GNPX	—	Small Cell Lung Cancer Extensive Stage	—
NCT04486833	Phase 2	Recruiting	Sponsor	GNPX	—	Carcinoma, Non-Small Cell Lung	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Genprex, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

GNPX — Genprex Inc.